Recent Posts
- Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update November 13, 2023
- Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production November 3, 2023
- Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program October 30, 2023
Pipeline and Technology
Corporate Address
Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenovia.com
Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update
NewsEyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production
NewsEyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program
NewsEyenovia To Present Data On Preservative-Free Microbial Integrity Of The Optejet®
NewsEyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference
NewsEyenovia Acquires U.S. Commercial Rights To APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) From Formosa Pharmaceuticals
NewsEyenovia Announces First Commercial Sale of MydCombi™
NewsEyenovia Announces Addition to Russell 2000® and Russell 3000® Indexes
NewsEyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform
NewsEyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update
News